Risk-based approach according to Annex I, part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberCAT/CPWP/686637/2011
Effective from12/02/2013
KeywordsAdvanced therapy medicinal products (ATMPs), risk-based approach, risk, risk factor
DescriptionThis document provides guidance on the application of the risk-based approach in the preparation of a marketing authorisation application. The concept of a ‘Risk-based approach’ has been introduced to the legislation with the revision of Annex 1, part IV of Directive 2001/83/EC as amended by Directive 2009/120 EC.

Document history

First version

Current version

Adopted guideline

Draft guideline

Concept paper

In operation: 12/02/2013–present

Published: 24/01/2012

Published: 26/01/2010

Related content

How helpful is this page?

Average rating:

 Based on 20 ratings

Add your rating:

See all ratings
4 ratings
4 ratings
4 ratings
4 ratings
4 ratings

Tell us more